openPR Logo
Press release

Clostridium difficile Infections Therapeutics Pipeline Analysis 2017

05-31-2017 04:12 PM CET | Health & Medicine

Press release from: ReportsnReports

Clostridium difficile Infections Therapeutics Pipeline

Clostridium difficile Infections Pipeline Review H2 2017 report provides comprehensive information on the therapeutics under development for Clostridium difficile Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridium difficile Infections and features dormant and discontinued projects.

Complete Report on Clostridium difficile Infections - Pipeline Review, H1 2017 available at http://www.reportsnreports.com/reports/1001393-clostridium-difficile-infections-pipeline-review-h1-2017.html

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Key Companies Analysed In Report: Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Biomar Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, Hsiri Therapeutics LLC, iCo Therapeutics Inc., Matinas BioPharma Holdings Inc, Merck & Co Inc, Nanomerics Ltd, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Sigma-Tau SpA, Vical Inc, Visterra Inc.

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1001393 . (This report is available at upto 25% Discount till June 02nd 2017.)

Drugs Profiles Analysed IN Report: , , Absynth Biologics Ltd , Actelion Ltd , AIMM Therapeutics BV 0, Akthelia Pharmaceuticals Ltd 0, AmpliPhi Biosciences Corp , Appili Therapeutics , Assembly Biosciences Inc , AvidBiotics Corp , CJ Therapeutics Inc , CaroGen Corp , Crestone Inc , Da Volterra SAS , Daiichi Sankyo Company Ltd , Evec Inc , GangaGen Inc , ImmunoBiology Ltd , Immuron Ltd , Inovio Pharmaceuticals Inc , Integrated BioTherapeutics Inc , Merck & Co Inc , MGB Biopharma Ltd , Microbiotix Inc , Micropharm Ltd 0, Miyarisan Pharmaceutical Company Ltd 0, Nabriva Therapeutics AG , Nanotherapeutics Inc , Novabiotics Ltd , NovoBiotic Pharmaceuticals LLC , Oragenics Inc , Otsuka Holdings Co Ltd , Pfizer Inc , Prokarium Ltd , Rebiotix Inc , Sanofi Pasteur SA , Second Genome Inc , Seres Therapeutics Inc , Serometrix LLC , Sorrento Therapeutics Inc , Summit Therapeutics Plc , Synthetic Biologics Inc , Valevia UK Ltd , Valneva SE , XBiotech Inc .

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Direct Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=1001393

Major Table OF Content
• Clostridium difficile Infections - Overview
• Clostridium difficile Infections - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies
• Clostridium difficile Infections - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Clostridium difficile Infections - Companies Involved in Therapeutics Development
• R&D Progress
• Clostridium difficile Infections - Dormant Projects
• Clostridium difficile Infections - Discontinued Products
• Clostridium difficile Infections - Product Development Milestones
• Featured News & Press Releases

ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@ reportsnreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clostridium difficile Infections Therapeutics Pipeline Analysis 2017 here

News-ID: 558928 • Views:

More Releases from ReportsnReports

DeviceCon Series 2024 - UK Edition | MarketsandMarkets
DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact! Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices. Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register MarketsandMarkets presents
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Conference Promises New Trends and Insights in Diagnosis
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH. This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March 2024| Challenges and Factors affecting in Sterilization of medical devices and more
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays. Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/ This conference aims to bring together all the stakeholders to discuss the obstacles in achieving
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, Surface and Forecast to 2025
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying

All 5 Releases


More Releases for Clostridium

Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of
Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of
The Global Clostridium Difficile Infection Treatment Market Driver
Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR
Clostridium Vaccine Market : Share, Analysis To 2024
The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong